Simcere Zaiming Pharmaceutical Co., Ltd.
Records under this name other than the patents Simcere Zaiming Pharmaceutical Co., Ltd. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 2 patents it holds.
Back to Simcere Zaiming Pharmaceutical Co., Ltd.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| 18/264,486 | Human CD33 Antibody and Use Thereof Pending Term is not computable until grant, so no date is shown and no estimate is implied. | Pending | Term is not computable until grant, so no date is shown and no estimate is implied. | |
| 18/266,125 | Anti-Egfr Nanobody and Use Thereof Pending Term is not computable until grant, so no date is shown and no estimate is implied. | Pending | Term is not computable until grant, so no date is shown and no estimate is implied. | |
| 18/266,393 | GPC3 Antibody and Application Thereof Pending Term is not computable until grant, so no date is shown and no estimate is implied. | Pending | Term is not computable until grant, so no date is shown and no estimate is implied. | |
| 18/267,518 | CD5 Antibody and Use Thereof now held by Hainan Simcere Zaiming Pharmaceutical Co., Ltd. Pending Term is not computable until grant, so no date is shown and no estimate is implied. | Pending | Term is not computable until grant, so no date is shown and no estimate is implied. | |
| 18/267,561 | HER2 Antibody and Application Thereof Pending Term is not computable until grant, so no date is shown and no estimate is implied. | Pending | Term is not computable until grant, so no date is shown and no estimate is implied. | |
| 18/272,539 | Anti-Human CD22 Monoclonal Antibodies and Use Thereof Pending Term is not computable until grant, so no date is shown and no estimate is implied. | Pending | Term is not computable until grant, so no date is shown and no estimate is implied. | |
| 18/275,529 | Monoclonal Antibody for Specifically Recognizing GLYPICAN-3, and Application Thereof now held by Hainan Simcere Zaiming Pharmaceutical Co., Ltd. Pending Term is not computable until grant, so no date is shown and no estimate is implied. | Pending | Term is not computable until grant, so no date is shown and no estimate is implied. | |
| 18/275,901 | Humanized GPC3 Antibody and Application Thereof now held by Hainan Simcere Zaiming Pharmaceutical Co., Ltd. Pending Term is not computable until grant, so no date is shown and no estimate is implied. | Pending | Term is not computable until grant, so no date is shown and no estimate is implied. | |
| 18/554,426 | Ubiquitin-Specific Protease 1 (USP1) Inhibitor now held by Hainan Simcere Zaiming Pharmaceutical Co., Ltd. Abandoned Abandoned Aug 5, 2026 | Abandoned | Abandoned Aug 5, 2026 | |
| 18/577,325 | CD19 Antibody and Application Thereof now held by Hainan Simcere Zaiming Pharmaceutical Co., Ltd. Pending Term is not computable until grant, so no date is shown and no estimate is implied. | Pending | Term is not computable until grant, so no date is shown and no estimate is implied. |